# What the Evidence Says About Rapamycin for Longevity

In 2026, while no clinical trial has definitively proven that rapamycin extends human lifespan, a robust and growing body of evidence indicates that low-dose, intermittent use is generally safe and yields targeted healthspan benefits in normative-aging adults. Recent human trials demonstrate measurable improvements in female lean muscle mass, partial preservation of ovarian reserve, and signs of enhanced immune function, though metabolic side effects still require strict medical monitoring. As massive, rigorously controlled Phase 3 clinical trials launch this year, the scientific community is finally shifting from promising animal models to concrete, human-centric physiological metrics.

## The Discovery and Evolution of a Miracle Macrolide

The narrative of rapamycin bridges exotic microbiology, transplant surgery, and modern geroscience. In 1975, a team of microbiologists studying soil samples collected from the shadow of the Moai statues on Easter Island—known natively as Rapa Nui—isolated a unique macrolide compound produced by the bacterium *Streptomyces hygroscopicus* [cite: 1, 2, 3]. Initially, researchers named the molecule rapamycin and recognized it for its potent antifungal properties [cite: 1, 3]. 

However, subsequent pharmacological investigations revealed that the compound possessed profound immunosuppressive capabilities [cite: 1]. For the next two decades, rapamycin was primarily developed to prevent the immune system from attacking foreign tissues. Under the generic name sirolimus, and the commercial brand name Rapamune, it received approval from the United States Food and Drug Administration (FDA) in 1999 as a prophylactic treatment against organ rejection in kidney transplant patients [cite: 1, 4, 5]. Later, its applications expanded to treat rare, progressive lung conditions such as lymphangioleiomyomatosis (LAM), as well as serving as a foundational molecule for advanced cancer treatments like temsirolimus and everolimus, which target the metabolic vulnerabilities of tumor cells [cite: 6, 7, 8].

The compound's trajectory shifted permanently when geroscientists began administering it to laboratory models. Across dozens of independent laboratories and research institutions over the last fifteen years, rapamycin has consistently extended the median lifespan of genetically heterogeneous mice [cite: 3, 9]. The results were staggering: depending on the specific strain, sex, and dosing protocol, rapamycin extended murine lifespan by roughly 10 to 25 percent [cite: 3, 9, 10]. 

Crucially, this lifespan extension occurred even when the drug was administered late in life—the equivalent of a 60-year-old human beginning the intervention [cite: 3, 11]. The National Institute on Aging's Interventions Testing Program (ITP), which represents the most rigorous multi-site mouse longevity program in existence, has repeatedly confirmed these findings, solidifying rapamycin as the most consistently replicated life-extending pharmacological intervention in mammalian biology [cite: 2, 3, 9]. A comprehensive 2025 meta-analysis encompassing 167 distinct studies confirmed that rapamycin prolongs lifespan in vertebrate species to a degree that is statistically comparable to dietary restriction, which has long been considered the gold standard intervention for promoting longevity [cite: 12]. In stark contrast, other popular geroprotective candidates evaluated in the same meta-analysis, such as the diabetes drug metformin, failed to produce a statistically significant lifespan extension across healthy vertebrates [cite: 12]. 

## Unpacking the Mechanism: How mTOR Controls the Biological Clock

To understand why a potent transplant drug might possess the ability to slow the systemic aging process, one must deeply understand its primary molecular target. Rapamycin operates by inhibiting a highly conserved, evolutionarily ancient protein kinase known as the mechanistic target of rapamycin, or mTOR [cite: 1, 2, 3]. 

mTOR functions as a master metabolic switch, a central command center that dictates how a cell utilizes its energy and resources based on the availability of nutrients in its environment [cite: 3, 11]. When nutrients—particularly amino acids and carbohydrates—are abundant, the mTOR pathway is highly active. It signals cells to shift into an anabolic state, synthesizing proteins, growing in size, and undergoing cellular division [cite: 3, 11, 12]. Evolutionarily, this system was beautifully wired to allow organisms to capitalize on transient periods of "feast," driving growth and reproduction when the environment could support it [cite: 3].

Conversely, when nutrients are scarce—such as during periods of fasting or severe caloric restriction—mTOR activity quiets down. This suppression shifts the cell from an anabolic growth state into a catabolic maintenance state [cite: 3, 13]. A critical downstream effect of this mTOR suppression is the robust activation of autophagy [cite: 11, 13]. Autophagy is essentially a cellular recycling and waste management process. It is responsible for degrading accumulated misfolded proteins, clearing out damaged organelles like dysfunctional mitochondria, and removing other damage-associated molecular patterns (DAMPs) that build up over time [cite: 11, 13].

In the modern human environment, food is constantly available. The evolutionary mechanism designed to handle periods of feast and famine is short-circuited because modern humans rarely experience famine. Consequently, the mTOR pathway rarely gets a break, meaning the vital "maintenance mode" of autophagy fires infrequently [cite: 3]. Chronically elevated mTOR activity correlates strongly with the acceleration of the fundamental hallmarks of aging [cite: 3, 13]. These include the rapid accumulation of senescent cells—dysfunctional cells that have stopped dividing but refuse to undergo apoptosis, instead secreting toxic inflammatory signals that damage surrounding tissue [cite: 3, 14]. Chronic mTOR activation also drives impaired protein homeostasis, faster telomere attrition, and an increased risk of age-related metabolic diseases, cancer, and neurodegeneration [cite: 1, 3, 11].

By directly binding to and inhibiting the mTOR protein kinase regardless of the actual nutrient status of the body, rapamycin acts as a chemical mimic of dietary restriction [cite: 3, 10, 11]. It essentially tricks the body's cells into believing they are starving, thereby activating similar longevity and repair pathways without requiring the organism to undergo actual malnourishment or severe caloric restriction [cite: 11, 12].

## The Dose Makes the Poison: Transplant Versus Longevity Protocols

When medical skeptics point out that rapamycin is a potent immunosuppressant prescribed to keep transplant patients from rejecting new kidneys, they are relying on factual medical history [cite: 15]. However, in pharmacology, the dose, the frequency, and the specific pharmacokinetic profile make the drug. The side effect profile and physiological impact of rapamycin at low, intermittent longevity doses are fundamentally different from its profile at chronic, daily transplant doses [cite: 11, 15].

The physiological divergence stems from the fact that the mTOR protein does not operate alone; it exists within cells in two distinct multi-protein complexes: mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) [cite: 11, 16, 17].

mTORC1 is the master regulator of cell growth, protein synthesis, and autophagy. Its chronic overactivity is directly linked to accelerated aging and age-related pathologies, and crucially, it is exquisitely and acutely sensitive to rapamycin [cite: 11, 13, 17, 18]. 

mTORC2, on the other hand, plays a more foundational role in basic metabolic regulation. It regulates cellular survival pathways, insulin signaling, glucose uptake in tissues, and the proliferation of vital immune cells [cite: 13, 18, 19]. In contrast to mTORC1, mTORC2 is relatively resistant to acute, short-term exposure to rapamycin, but its structure and function become severely disrupted upon prolonged, continuous treatment with the drug [cite: 16, 17, 18, 19].

In the context of transplant medicine and oncology, physicians deliberately seek to suppress the immune system and halt cellular proliferation to prevent organ rejection or tumor growth. Therefore, they prescribe daily doses of rapamycin—typically 2 to 5 milligrams per day after a high initial loading dose—to maintain high, continuous trough concentrations of the drug in the patient's bloodstream [cite: 7, 19, 20]. This chronic, unyielding exposure deeply inhibits both mTORC1 and mTORC2 [cite: 17, 19]. It is specifically the off-target inhibition of mTORC2 that leads to the classic and severe side effects associated with rapamycin therapy: profound systemic immunosuppression, insulin resistance, glucose intolerance, hyperlipidemia, and impaired tissue repair [cite: 11, 16, 18, 19].

Longevity researchers and physicians have adapted a completely different pharmacological strategy based on emerging preclinical data. By utilizing an intermittent dosing schedule, the goal is to safely thread the needle between efficacy and toxicity [cite: 16, 18, 19]. This protocol typically involves a single dose of roughly 3 to 10 milligrams taken once a week [cite: 19, 21]. This causes the drug concentration in the blood to peak sharply, reaching levels high enough to deeply inhibit mTORC1 and trigger the beneficial cascades of autophagy and cellular cleanup. Over the next several days, the drug naturally clears from the system [cite: 18, 19, 21]. Because the exposure is not continuous, mTORC2 function is largely spared, allowing the patient to reap the geroprotective benefits of mTORC1 inhibition without compromising their basal insulin sensitivity or broadly suppressing their immune system [cite: 13, 16, 18, 19]. 

To fully understand this paradigm shift, it is essential to review the contrasting clinical variables. Chronic daily dosing strongly suppresses both mTOR complexes, leading to desired immunosuppression but unintended metabolic side effects. Intermittent weekly dosing aims to selectively inhibit mTORC1 to trigger cellular repair (autophagy) while allowing mTORC2 to rebound, maintaining normal insulin sensitivity and basal immune function.

### Clinical Regimen Comparison: Transplant vs. Longevity Paradigms

| Parameter | Transplant / Oncology Protocol | Longevity / Healthspan Protocol |
| :--- | :--- | :--- |
| **Dosing Frequency** | Daily (Continuous exposure) [cite: 19, 22] | Intermittent (Typically once weekly) [cite: 19, 21] |
| **Typical Adult Dose** | 2–5 mg daily (following a 6 mg loading dose) [cite: 7, 22] | 3–10 mg once weekly (approx. 0.075–0.15 mg/kg) [cite: 19, 21] |
| **Target Pathway** | Sustained inhibition of both mTORC1 and mTORC2 [cite: 17, 19] | Selective, acute inhibition of mTORC1 [cite: 13, 18, 19] |
| **Immune System Effect** | Intentional and profound immunosuppression [cite: 7, 19] | Immunomodulation / Partial reversal of immunosenescence [cite: 2, 3, 18] |
| **Metabolic Risk Profile** | High risk of insulin resistance and hyperlipidemia [cite: 11, 18] | Low to moderate risk, dependent on baseline health and dosing [cite: 3, 11, 19] |
| **Therapeutic Goal** | Prevent allograft rejection or arrest tumor proliferation [cite: 4, 23, 24] | Induce autophagy, clear senescent cells, delay age-related decline [cite: 3, 6, 25] |

## 2026 Update: What Human Clinical Trials Actually Show

For many years, the human evidence for rapamycin's longevity benefits was largely anecdotal or drawn from observational surveys. A widely cited survey of 333 self-reported off-label rapamycin users indicated high perceived quality of life and general health improvements with generally mild side effects, but such data suffers from extreme selection bias and cannot establish definitive causation [cite: 3, 26]. Similarly, an observational study from the Mayo Clinic, tracking 1,200 older adults using off-label rapamycin, suggested a 23% reduction in all-cause mortality over a four-year follow-up compared to age-matched controls [cite: 27]. While these observational signals were strong, the scientific community demanded rigorous, placebo-controlled trials. Since 2024, the field has finally transitioned into an era of formal clinical testing designed to evaluate concrete physiological outcomes in healthy humans.

### The PEARL Trial: Body Composition and Lean Mass

Published in the journal *Aging* in April 2025, the Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial represented a watershed moment. It was the first completed, long-term, randomized, double-blind, placebo-controlled clinical trial specifically evaluating the safety and efficacy of rapamycin for healthy aging in humans [cite: 3, 28, 29]. 

Funded through a crowdfunded initiative by Lifespan.io and AgelessRx, the trial followed 114 normative-aging adults, ranging in age from 50 to 85, over a 48-week period [cite: 28, 29, 30]. The participants were randomly assigned to receive either a placebo, a 5 mg weekly dose of rapamycin, or a 10 mg weekly dose of rapamycin [cite: 28, 29]. The primary clinical endpoint of the study was a measurable reduction in visceral adiposity (belly fat) as quantified by advanced DXA scans [cite: 28, 31, 32].

On its primary endpoint, the PEARL trial did not succeed. Visceral adiposity did not change to a statistically significant degree between the rapamycin groups and the placebo group ($p = 0.942$) [cite: 31, 32, 33]. Furthermore, no significant differences were observed in standard safety blood biomarkers or in broad reductions of systemic biological age based on early epigenetic clock models [cite: 9, 31].

However, the secondary endpoints of the PEARL trial revealed highly intriguing, sex-specific clinical benefits. Women in the 10 mg weekly high-dose group experienced a statistically significant improvement in lean tissue mass ($\eta_p^2 = 0.202$, $p = 0.013$) and a significant reduction in self-reported physical pain ($\eta_p^2 = 0.168$, $p = 0.015$) over the 48 weeks [cite: 28, 31, 32]. Male participants in the 10 mg group showed trends toward improved bone mineral density, though the results narrowly missed statistical significance ($p = 0.061$) [cite: 31]. Meanwhile, participants taking the lower 5 mg dose reported significant, quantifiable improvements in their self-assessed general health ($\eta_p^2 = 0.166$, $p = 0.004$) and emotional well-being ($\eta_p^2 = 0.108$, $p = 0.023$) [cite: 3, 32].

Most importantly, the PEARL trial established a strong safety profile for intermittent, low-dose rapamycin use over a prolonged period. Across the entire year, moderate to severe adverse events occurred at similar rates across all three groups [cite: 28, 31, 32]. The most frequent minor complaint among those taking the active drug was mild gastrointestinal discomfort [cite: 28, 34]. The researchers did highlight a major limitation in their post-trial analysis: to create a perfectly matching placebo, the trial utilized a specifically compounded capsule of rapamycin. Subsequent pharmacokinetic testing revealed that this compounded formulation possessed only roughly 31% of the bioavailability of commercially manufactured sirolimus tablets [cite: 21, 28, 30]. Consequently, the actual systemic drug exposure experienced by the participants was significantly lower than the intended 5 mg and 10 mg parameters, which may explain the failure to impact the primary endpoint of visceral fat [cite: 28, 29].

### The VIBRANT Trial: Slowing Female Reproductive Aging

One of the most profound and unexpected developments in geroscience emerged from Columbia University's Validating Benefits of Rapamycin for Reproductive Aging Treatment (VIBRANT) study, led by Dr. Zev Williams and Dr. Yousin Suh [cite: 3, 35, 36]. 

The ovaries are unique organs that undergo biological aging significantly faster than the rest of the human body, driving the onset of menopause, the loss of fertility, and a cascade of associated systemic health declines [cite: 35]. The mTOR pathway has been identified as playing a direct and critical role in this process; mTOR promotes the activation and recruitment of dormant ovarian follicles during each menstrual cycle [cite: 3, 36]. 

The VIBRANT trial administered a 5 mg weekly dose of rapamycin to healthy, reproductive-age women between 38 and 45 years old to test whether mTOR inhibition could preserve ovarian reserve [cite: 3, 36]. Early results reported in 2024 and expanded upon in 2025 demonstrated an approximate 20% reduction in the clinical rate of ovarian aging [cite: 3, 35, 36]. While a woman typically loses roughly 50 mature eggs during each monthly cycle, the women on the weekly rapamycin protocol experienced a slowed rate, releasing and losing only about 15 eggs per month [cite: 35]. 

By preventing the unnecessary activation of dormant follicles, rapamycin theoretically preserves the ovarian reserve over time. The implications of this research are vast. Delaying the onset of menopause could have transformative downstream effects on a woman's overall healthspan, potentially extending fertility while significantly delaying the elevated risks of cardiovascular disease, cognitive decline, and severe bone density loss that frequently accompany the postmenopausal state [cite: 35].

### Neurological and Multi-Organ Imaging: The Karolinska Pilot

The potential for rapamycin to mitigate neurodegeneration is currently a frontier of intense study. In early 2026, researchers from the Karolinska Institute in Sweden published the results of an advanced Phase 2a pilot trial (EudraCT 2023-000127-36) evaluating rapamycin in older patients diagnosed with mild cognitive impairment (MCI) and early-stage Alzheimer's disease [cite: 31, 37, 38]. 

Fourteen participants were enrolled and given 7 mg of commercial rapamycin (Rapamune) once weekly for a duration of 26 weeks [cite: 37, 38]. While the study was a small, open-label pilot primarily intended to test the feasibility of implementing a multi-modal, multi-organ imaging battery, the collected exploratory efficacy data revealed unexpected systemic benefits extending far beyond the brain [cite: 37, 38]. 

Through detailed exposure-response analyses, researchers discovered that higher blood concentrations of rapamycin correlated significantly with greater skeletal muscle density ($r = 0.64$, $p = 0.035$) and trended toward a smaller loss of muscle cross-sectional area [cite: 37, 38]. Furthermore, the advanced imaging protocols captured nominally significant increases in baseline cardiac output ($p = 0.017$), improvements in left retinal ganglion cell layer thickness ($p = 0.044$), and enhanced optic nerve head glucose uptake ($p = 0.040$) [cite: 37, 38]. These findings provide early, compelling human evidence that intermittent mTOR inhibition may yield structural and functional improvements concurrently across the cardiovascular, ocular, and musculoskeletal systems in older adults [cite: 37, 38].

### The Paradox of Immunosenescence and Inflammaging

One of the longest-standing fears regarding the use of an immunosuppressant for healthy aging is its potential to increase the risk of infectious diseases. However, a growing body of low-dose clinical data suggests the opposite may be true for the elderly [cite: 2, 25]. 

Biological aging severely dysregulates the human immune system. The targeted adaptive immune response responsible for fighting specific viral and bacterial threats weakens—a process known as immunosenescence [cite: 9, 25]. Simultaneously, background, non-specific inflammation runs chronically high, causing systemic tissue damage—a phenomenon termed inflammaging [cite: 9, 39]. 

In a landmark 2014 study conducted by Novartis and led by Dr. Joan Mannick, older adults given a low-dose rapamycin analog for six weeks exhibited a robust 20% improvement in their immune response to an influenza vaccine relative to a placebo group [cite: 3]. They also showed a marked reduction in the proportion of exhausted T-cells circulating in their blood [cite: 3]. 

Further supporting this mechanism, a 2025 study from Oxford University investigated how mTOR inhibition fundamentally alters human T-cells at a cellular level [cite: 14]. Researchers found that T-cells treated with rapamycin exhibited significantly lower levels of p21, a primary biological marker of cellular senescence [cite: 14]. Moreover, the rapamycin-treated immune cells were three times more likely to survive exposure to a DNA-damaging antibiotic agent called zeocin [cite: 14]. This data suggests that low-dose mTOR inhibition effectively quiets the overactive, damaging background inflammation of inflammaging while simultaneously allowing the targeted, adaptive immune responses to function more effectively against genuine external threats [cite: 9, 14].

## Profiling the Risks and Side Effects in Healthy Adults

While the safety profile of intermittent longevity dosing is distinct from and far superior to chronic transplant dosing, it is vital to acknowledge that rapamycin is not a benign dietary supplement; it is a highly potent prescription pharmaceutical. Clinical supervision is widely considered essential by longevity physicians to manage and mitigate the known risks of the intervention [cite: 11, 15].

### Mucosal Ulcers and Oral Health
The most consistently reported adverse side effect in healthy adults taking low-dose rapamycin is the development of aphthous ulcers, commonly known as canker sores or mouth ulcers [cite: 2, 22]. This condition is clinically termed mTOR inhibitor-associated stomatitis (mIAS) [cite: 26]. 

Data extracted from a comprehensive 2024 secondary analysis of 333 self-reported off-label rapamycin users revealed that approximately 26% of individuals experience some form of oral health changes [cite: 26, 40]. However, contrary to expectations from transplant literature, the ulcers experienced by longevity users are predominantly transient and mild. Of the 54 users in the cohort who reported ulcers, 50 classified them as intermittent—meaning they disappeared with continued usage or only emerged early in the regimen [cite: 26]. Only 4 individuals reported persistent ulcers [cite: 26]. Interestingly, dose-response relationships suggest a paradox: higher weekly doses (averaging 6.87 mg/week) were associated with the milder, intermittent ulcers, whereas lower weekly doses (averaging 3.6 mg/week) were occasionally linked to persistent sores, suggesting complex interactions with immune shifts or the oral microbiome [cite: 26, 40].

### Metabolic Dysregulation and Starvation Pseudo-Diabetes
Even with weekly intermittent dosing designed to spare mTORC2, rapamycin can interfere with lipid and glucose metabolism. Elevated levels of LDL cholesterol and blood triglycerides are commonly observed in clinical tracking [cite: 11, 14]. 

In both human subjects and animal models, prolonged rapamycin exposure can induce a metabolic phenomenon known as "starvation pseudo-diabetes" [cite: 11, 41]. Because rapamycin mimics a state of severe nutrient scarcity, the body reacts by downregulating insulin production and upregulating glucose in the bloodstream to preserve energy for the brain—leading to mild glucose intolerance and transient insulin resistance [cite: 41]. Though prominent researchers argue this state is a benign, entirely reversible biological artifact of fasting mimicry rather than pathological Type 2 diabetes, clinicians universally recommend the strict baseline and ongoing monitoring of fasting lipids, blood glucose, and HbA1c levels for any patient on a rapamycin protocol [cite: 3, 15, 25, 41].

### Wound Healing and Infection Risk
Because the mTOR pathway is absolutely necessary for cellular proliferation and tissue growth, rapamycin can inherently impair wound healing and delay tissue repair following physical trauma [cite: 11, 14, 25]. Patients engaged in longevity protocols are universally advised by prescribing physicians to immediately discontinue the drug prior to scheduled surgeries, major dental work, or during active, severe bacterial or viral infections to allow the immune and repair systems to mount a full response [cite: 3, 7].

## The Gold Standard: The University of Arizona Phase 3 Trial

Despite the promising biological signals in body composition, female fertility, and immune function, the geroscience field has historically lacked the massive, multi-year, rigorously controlled human data required to satisfy mainstream regulatory bodies like the FDA. The evidence base has been criticized as preliminary and limited by small sample sizes or heterogeneous outcomes [cite: 33].

That dynamic is poised to change dramatically in 2026. The University of Arizona R. Ken Coit College of Pharmacy has officially launched the largest, longest, and most definitive human longevity trial of rapamycin to date, backed by a transformative $12 million in philanthropic funding from alumnus R. Ken Coit [cite: 42, 43, 44]. 

Led by principal investigator Dr. Bonnie LaFleur, the Phase 3, double-blind, randomized clinical trial aims to enroll 720 adults aged 65 and older [cite: 42, 44, 45]. To avoid the compounding bioavailability issues that plagued the PEARL trial, the Arizona team is utilizing standardized 2 mg commercial pills (Rapamune) to ensure precise, replicable pharmacokinetics across the entire cohort [cite: 45, 46]. Participants will take the drug or a matching placebo for a full two years, followed by an additional one-year observational follow-up period [cite: 42, 43, 44]. 

Crucially, the trial bypasses subjective biological age epigenetic clocks in favor of two concrete, highly physiological co-primary endpoints designed to definitively prove clinical resilience in the elderly [cite: 45, 46]:
1.  **Frailty Transition:** The trial will measure whether rapamycin can physically halt or slow the transition from a robust, independent state to a "pre-frail" or frail state in older adults. This will be tracked using functional, real-world parameters such as grip strength, mobility, and exhaustion levels [cite: 44, 45, 46]. 
2.  **IL-6 Reduction:** Interleukin-6 (IL-6) is a primary molecular marker of chronic inflammation (inflammaging). It is tightly associated with the progression of cardiovascular disease, cognitive decline, muscle loss, and metabolic dysfunction [cite: 42, 45, 46]. 

If rapamycin successfully reduces systemic IL-6 levels and statistically slows the functional transition to frailty over a two-year period in a population of 720 older adults, it will provide the first direct, indisputable evidence that mTOR modulation can alter the physical biology of human aging at a systemic clinical level, bridging the gap between promising candidate and standard-of-care medical reality [cite: 45, 46]. 

## The Future of Geroscience: Precision Longevity in 2026

The exploration of rapamycin is occurring within a rapidly maturing field of geroscience. At major scientific gatherings, such as the 12th Aging Research and Drug Discovery (ARDD) meeting held in 2025 and 2026 in Copenhagen, the discourse has shifted decisively away from descriptive mouse studies toward actionable, human-centric interventions [cite: 39, 47, 48]. 

Researchers are increasingly analyzing rapamycin alongside a suite of other interventions that target different biological hallmarks of aging. For instance, while rapamycin targets nutrient sensing and autophagy, drugs like SGLT2 inhibitors and next-generation GLP-1 agonists are being tested for their ability to improve vascular health and systemic metabolic function independent of weight loss [cite: 49, 50, 51]. Similarly, compounds like alpha-ketoglutarate (AKG) and NAD+ precursors are being evaluated in specific patient populations to restore youthful cellular metabolism and epigenetic profiles [cite: 52, 53, 54].

Dr. Andrea Maier, a leading geroscientist at the National University of Singapore and the founding president of the Healthy Longevity Medicine Society, highlights that the field is pivoting toward "precision geromedicine" [cite: 48, 53]. Using deep-phenotyped cohorts like the SG90 study of Asian octogenarians, researchers are utilizing multi-omics, lipidomics, and organ-specific biological clocks to understand exactly *how* different systems age in different individuals [cite: 55, 56, 57]. The future of rapamycin therapy will likely not be a one-size-fits-all prescription. Instead, treatment will be highly stratified and mechanism-matched—prescribed dynamically based on an individual's unique genetic profile, menopausal status, and specific organ-level biological age markers [cite: 25, 48, 53].

## Bottom line

As of 2026, the scientific community lacks definitive Phase 3 clinical proof that rapamycin extends human lifespan, and its off-label usage requires meticulous medical monitoring for lipid and glucose metabolic shifts. However, current clinical evidence robustly supports that intermittent, low-dose administration is well-tolerated in normative-aging adults and yields tangible, tissue-specific physiological benefits, notably improving lean tissue mass in women and partially preserving female ovarian reserve. With the University of Arizona's massive 720-person Phase 3 clinical trial currently underway, the field is perfectly positioned to determine whether targeted mTOR inhibition can successfully prevent frailty and reverse systemic inflammation in the aging human population over the long term.

## Sources

1. [Dr. Gerstman Substack: Longevity Medicine Fact Check](https://drgerstman.substack.com/p/is-longevity-medicine-is-the-latest)
2. [Frontiers in Aging: Phase 3 Rapamycin Human Longevity Trial](https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1628187/full)
3. [ResearchGate: Rapamycin for longevity: the pros, the cons, and future perspectives](https://www.researchgate.net/publication/393465452_Rapamycin_for_longevity_the_pros_the_cons_and_future_perspectives)
4. [ResearchGate: Blazing a trail for the clinical use of rapamycin as a geroprotecTOR](https://www.researchgate.net/publication/374504334_Blazing_a_trail_for_the_clinical_use_of_rapamycin_as_a_geroprotecTOR)
5. [Lifespan.io: Impact of off-label low-dose rapamycin](https://lifespan.io/impact-of-off-label-low-dose-rapamycin-on-healthy-adults/)
6. [PMC: Low dose rapamycin therapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC12422820/)
7. [PMC: Oral health of off-label rapamycin users](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335702/)
8. [ResearchGate: Evaluation of off-label rapamycin use on oral health](https://www.researchgate.net/publication/381222994_Evaluation_of_off-label_rapamycin_use_on_oral_health)
9. [PubMed: Evaluation of oral health](https://pubmed.ncbi.nlm.nih.gov/38839644/)
10. [NAD.com: New Oxford study on rapamycin and cell senescence](https://www.nad.com/news/new-oxford-study-powerful-longevity-drug-rapamycin-targets-cell-senescence)
11. [PMC: mTOR pathway and the function of rapamycin](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/)
12. [PMC: Rapamycin side effects and pseudo-diabetes](https://pmc.ncbi.nlm.nih.gov/articles/PMC6814615/)
13. [Hillary Lin MD: Rapamycin for Longevity Guide](https://hillarylinmd.com/guides/rapamycin-longevity)
14. [Weizmann Institute: Long Life in a Pill (PDF)](https://www.weizmann.ac.il/mcb/alon/sites/mcb.alon/files/users/user56/Chapter%2010%20-%20long%20life%20in%20a%20pill.pdf)
15. [Columbia OBGYN: Ground-breaking VIBRANT clinical trial](https://reports.obgyn.columbia.edu/2024-annual-report/ground-breaking-clinical-trial-explores-delaying-menopause/)
16. [Roseway Labs: Longevity medicine](https://rosewaylabs.com/longevity-medicine-the-science-of-extending-healthspan/)
17. [GetHealthspan: Rapamycin for women](https://www.gethealthspan.com/research/article/rapamycin-for-women)
18. [Aging-US: PEARL trial results press release](https://www.aging-us.com/news-room/low-dose-rapamycin-improves-muscle-mass-and-well-being-in-aging-adults)
19. [ResearchGate: Safety and efficacy of rapamycin - PEARL Trial](https://www.researchgate.net/publication/383334928_Safety_and_efficacy_of_rapamycin_on_healthspan_metrics_after_one_year_PEARL_Trial_Results)
20. [FoodMedCenter: Can rapamycin slow aging?](https://foodmedcenter.org/rapamycin-slow-aging/)
21. [Aging-US: Influence of rapamycin on safety and healthspan](https://www.aging-us.com/article/206235)
22. [Longevity Germany: Rapamycin guide](https://longevity-germany.com/en/guide/rapamycin-deutschland)
23. [PMC: Chronic treatment with mTOR inhibitor rapamycin](https://pmc.ncbi.nlm.nih.gov/articles/PMC6909887/)
24. [Lamming Lab: Mannick and Lamming 2023 Review (PDF)](https://lamminglab.medicine.wisc.edu/wp-content/uploads/sites/1341/2023/12/Mannick-and-Lamming-2023-Nature-Aging.pdf)
25. [PMC: mTORC1 vs mTORC2 inhibition](https://pmc.ncbi.nlm.nih.gov/articles/PMC4852795/)
26. [Ubie Health: Rapamycin longevity science](https://ubiehealth.com/doctors-note/rapamycin-longevity-science-mtor-inhib-lifespan-6721e2)
27. [Rapamycin News: Dosing and peak mTOR inhibition](https://www.rapamycin.news/t/rapamycin-dosing-and-peak-mtor-inhibition/18166)
28. [Rapamycin News: NUS Clinical Trials Ongoing](https://www.rapamycin.news/t/nus-clinical-trials-ongoing/18584)
29. [GetHealthspan: Human rapamycin trial longevity evidence](https://www.gethealthspan.com/research/article/human-rapamycin-trial-longevity-evidence)
30. [PubMed: Rapamycin and its derivatives in adults](https://pubmed.ncbi.nlm.nih.gov/38310895/)
31. [Lifespan.io: Results of a crowdfunded one-year human rapamycin trial](https://lifespan.io/results-of-a-crowdfunded-one-year-human-rapamycin-trial/)
32. [Fight Aging: Academic Clinical Trials for Rapamycin](https://www.fightaging.org/archives/2026/04/academic-clinical-trials-for-rapamycin-to-answer-questions-on-dosing-for-anti-aging-use/)
33. [News-Medical: Low-dose rapamycin shows promise](https://www.news-medical.net/news/20250507/Low-dose-rapamycin-shows-promise-for-enhancing-healthspan-in-older-adults.aspx)
34. [Rapamycin News: May 2026 Clinical Studies in Aging](https://www.rapamycin.news/t/may-2026-clinical-studies-in-aging/24662)
35. [NAD.com: Rapamycin extends life as much as dieting](https://www.nad.com/news/anti-aging-drug-rapamycin-extends-life-as-much-as-dieting-new-study-shows)
36. [ResearchGate: Spermidine ameliorates hepatic steatosis](https://www.researchgate.net/publication/346873596_Spermidine_ameliorates_high-fat_diet-induced_hepatic_steatosis_and_adipose_tissue_inflammation_in_preexisting_obese_mice)
37. [FoundMyFitness: Diet and lifestyle tags](https://www.foundmyfitness.com/tags/diet)
38. [ResearchGate: Oleoylethanolamide increases PPAR-A](https://www.researchgate.net/publication/325254931_Oleoylethanolamide_increases_the_expression_of_PPAR-A_and_reduces_appetite_and_body_weight_in_obese_people_A_clinical_trial)
39. [GetHealthspan: Rapamycin side effects longevity doses](https://gethealthspan.com/research/article/rapamycin-side-effects-longevity-doses)
40. [PMC: Long-term mTOR inhibition side effects](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/)
41. [GetHealthspan: Rapamycin dosing for longevity](https://www.gethealthspan.com/research/article/rapamycin-dosing-for-longevity)
42. [YouTube: Dr. Lucia Aronica on Rapamycin](https://www.youtube.com/watch?v=ISLct7V4-aQ)
43. [Augment Life Shop: Rapamycin for longevity uses](https://augmentlifeshop.com/blogs/extending-healthy-lifespan/rapamycin-for-longevity-uses-dosage-side-effects)
44. [Dr. Oracle AI: Recommended dosage of Rapamycin](https://www.droracle.ai/articles/319171/what-is-the-recommended-dosage-and-usage-of-rapamycin)
45. [PatSnap: Approved indications for Sirolimus](https://synapse.patsnap.com/article/what-are-the-approved-indications-for-sirolimus)
46. [Drugs.com: Sirolimus dosage](https://www.drugs.com/dosage/sirolimus.html)
47. [FDA: Rapamune Prescribing Information (PDF)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s059,021110s076lbl.pdf)
48. [My American Nurse: FDA approves drug for rare lung disease](https://www.myamericannurse.com/fda-approves-drug-rare-lung-disease/)
49. [Valhalla Vitality: Sirolimus Dosage Key Considerations](https://valhallavitality.com/blog/sirolimus-dosage-key-considerations-and-guidelines)
50. [Dr. Oracle AI: Recommended dosing for longevity](https://www.droracle.ai/articles/589463/what-is-the-recommended-dosing-for-rapamycin-sirolimus-for)
51. [Rapamycin News: Cancer patients and rapamycin doses](https://www.rapamycin.news/t/cancer-patients-and-rapamycin-doses/1244/5)
52. [BMJ: Risk of cancer and death in patients treated with sirolimus (PDF)](https://epub.ub.uni-muenchen.de/37219/1/bmj.g6679.full.pdf)
53. [PMC: Sirolimus and cancer incidence](https://pmc.ncbi.nlm.nih.gov/articles/PMC4567030/)
54. [Live Forever Club: Resources and events](https://liveforever.club/page/life-extension/resources?display=all)
55. [ImmortalityLab: Next-generation GLP-1 drugs](https://immortalitylab.ai/news/glp1-next-generation-drugs)
56. [ImmortalityLab: GLP-1 trials re-examined](https://immortalitylab.ai/news/glp1-longevity-secondary-endpoints)
57. [ImmortalityLab: Fasting and autophagy biomarker trial](https://immortalitylab.ai/news/fasting-autophagy-human-trial)
58. [ImmortalityLab: GlyNAC pilot results](https://immortalitylab.ai/news/glycine-nac-pilot-results)
59. [Digital Journal: Improving immune function trial launched](https://www.digitaljournal.com/tech-science/improving-immune-function-rapamycin-clinical-trial-launched/article)
60. [University of Arizona News: U of A launches rapamycin trial](https://news.arizona.edu/news/u-launches-rapamycin-clinical-trial-philanthropic-support-alumnus-ken-coit)
61. [YouTube: U of A Clinical Trial Presentation](https://www.youtube.com/watch?v=rpcU6l6Onms)
62. [U of A College of Pharmacy: Can a drug slow aging?](https://www.pharmacy.arizona.edu/news/2026/can-drug-slow-aging-rapamycin-story)
63. [Dog Aging Project: TRIAD Clinical Trial](https://dogagingproject.org/project-details)
64. [Google Search: Time in United Kingdom](https://www.google.com/search?q=time+in+United+Kingdom)
65. [Google Search: Time in Singapore](https://www.google.com/search?q=time+in+Singapore)
66. [Rapamycin News: ARDD 2025 Meeting Videos](https://www.rapamycin.news/t/ardd-2025-meeting-videos-now-available/23224)
67. [Rapamycin News: ARDD 2025 Videos Page 2](https://www.rapamycin.news/t/ardd-2025-meeting-videos-now-available/23224?page=2)
68. [Aging-US: ARDD 2025 actionable longevity interventions](https://www.aging-us.com/article/206368/text)
69. [ResearchGate: Toward actionable interventions 12th ARDD](https://www.researchgate.net/publication/403550680_Toward_actionable_interventions_in_human_aging_12th_ARDD_meeting_2025)
70. [AgingPharma: ARDD 2025 Speakers](https://agingpharma.org/speakers2025)
71. [ResearchGate: Activity of sirolimus in MDS](https://www.researchgate.net/publication/8008720_Activity_of_sirolimus_in_patients_with_myelodysplastic_syndrome_-_Results_of_a_pilot_study)
72. [ResearchGate: Diabetes-Associated Cognitive Dysfunction](https://www.researchgate.net/publication/391249369_Risk_Factors_Pathological_Changes_and_Potential_Treatment_of_Diabetes-Associated_Cognitive_Dysfunction)
73. [ResearchGate: Multiomics study in Rheumatoid Arthritis](https://www.researchgate.net/publication/403698053_Transformer-based_multi-omics_study_identifies_important_role_of_glycine_serine_and_threonine_metabolism_pathway_in_rheumatoid_arthritis_complicated_by_anemia)
74. [ResearchGate: Alpha-Solanine as potential anticancer agent](https://www.researchgate.net/publication/383521351_Updated_aspects_of_alpha-Solanine_as_a_potential_anticancer_agent_Mechanistic_insights_and_future_directions)
75. [ResearchGate: l-Carnitine in Colorectal Cancer](https://www.researchgate.net/publication/389832911_l-Carnitine_and_Acetyl-l-Carnitine_Induce_Metabolism_Alteration_and_Mitophagy-Related_Cell_Death_in_Colorectal_Cancer_Cells)
76. [NUS Medicine: Graduate Studies Projects (PDF)](https://medicine.nus.edu.sg/graduatestudies/wp-content/uploads/sites/16/2022/11/List-of-research-projects-available-for-prospective-graduate-students-Nov-2022-v2.pdf)
77. [ResearchGate: Animal Models of Aging Research](https://www.researchgate.net/publication/272512378_Animal_Models_of_Aging_Research_Implications_for_Human_Aging_and_Age-Related_Diseases)
78. [ResearchGate: Brian Kennedy Profile](https://www.researchgate.net/profile/Brian-Kennedy-18)
79. [ResearchGate: Rajkumar Dorajoo Profile](https://www.researchgate.net/profile/Rajkumar-Dorajoo)
80. [ResearchGate: Gut metagenomes of Asian octogenarians](https://www.researchgate.net/publication/383791650_Gut_metagenomes_of_Asian_octogenarians_reveal_metabolic_potential_expansion_and_distinct_microbial_species_associated_with_aging_phenotypes)
81. [Rapamycin News: Andrea Maier Trial Results](https://www.rapamycin.news/t/ardd-2025-meeting-videos-now-available/23224)
82. [Aging-US: Andrea Maier at ARDD](https://www.aging-us.com/article/203859/text)
83. [Lifespan.io: Andrea Maier on longevity medicine](https://lifespan.io/andrea-maier-on-longevity-medicine-for-all/)
84. [Purovitalis: Most studied longevity supplements](https://purovitalis.com/most-studied-longevity-supplements/)
85. [Lifespan.io: Geroscience in 2025 Expert Roundup](https://lifespan.io/geroscience-in-2025-the-expert-roundup/)
86. [Google Search: Time in Japan](https://www.google.com/search?q=time+in+Japan)
87. [Google Search: Time in Singapore](https://www.google.com/search?q=time+in+Singapore)
88. [Google Search: Time in China](https://www.google.com/search?q=time+in+China)
89. [GetHealthspan: University of Arizona trial details](https://www.gethealthspan.com/research/article/human-rapamycin-trial-longevity-evidence)
90. [University of Arizona News: U of A trial frailty and IL-6](https://news.arizona.edu/news/u-launches-rapamycin-clinical-trial-philanthropic-support-alumnus-ken-coit)
91. [U of A Pharmacy: Can drug slow aging details](https://www.pharmacy.arizona.edu/news/2026/can-drug-slow-aging-rapamycin-story)
92. [Rapamycin News: U of A 12 million trial](https://www.rapamycin.news/t/university-of-arizona-launches-12-million-rapamycin-clinical-trial/24165)
93. [U of Arizona Medicine: Frailty SIP Final (PDF)](https://medicine.arizona.edu/sites/default/files/2026-04/Frailty-SIP-Final-pdf.pdf)
94. [ResearchGate: EudraCT trial results healthy adults](https://www.researchgate.net/publication/383334928_Safety_and_efficacy_of_rapamycin_on_healthspan_metrics_after_one_year_PEARL_Trial_Results)
95. [ResearchGate: Multi-modal imaging in Alzheimer's Pilot](https://www.researchgate.net/publication/402173579_Multi-modal_and_multi-organ_in_vivo_imaging_to_assess_geroprotective_interventions_in_humans_results_from_a_pilot_trial_of_rapamycin_in_Alzheimer's_Disease)
96. [MedRxiv: Multi-modal imaging EudraCT preprint (PDF)](https://www.medrxiv.org/content/10.64898/2026.03.11.26348179v1.full.pdf)
97. [MDPI: Investigational approaches in psychiatry](https://www.mdpi.com/2076-3425/15/2/161)
98. [ICR: Clinical trials in oncology](https://www.icr.ac.uk/research-and-discoveries/find-a-researcher/test-researcher-profile-detail/professor-judith-bliss)
99. [MedRxiv: PEARL Trial Preprint](https://www.medrxiv.org/content/10.1101/2024.08.21.24312372v1)
100. [PMC: PEARL trial full text](https://pmc.ncbi.nlm.nih.gov/articles/PMC12074816/)
101. [Hillary Lin MD: Rapamycin Guide](https://hillarylinmd.com/guides/rapamycin-longevity)
102. [Lifespan Asia: Rapamycin in 2026](https://lifespan.asia/rapamycin-for-longevity-in-2026-the-science-dosing-protocols-and-what-the-research-actually-shows/)
103. [Fight Aging: Academic Clinical Trials](https://www.fightaging.org/archives/2026/04/academic-clinical-trials-for-rapamycin-to-answer-questions-on-dosing-for-anti-aging-use/)

**Sources:**
1. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAh9S3Hn-3Z9tGy67b_SYqLVTCsMbeposEP8HHcZ7KZKJvre12vtXhG9G9gXmZkAkVex6lwoyUJToGogAOhDsNTSOtEc2YlHmh_sBvfC-6rYYEChacEroMc5Cc1CedbNh85tn1vDUVMbov4Li2ESNvtI4Y17UBIR2Xlrd38kcsDLhkAW-LdMBYwHkwmCKvVFVlHJvjYesUFak3T2V-z3q2Ra5fCFlyBfZD)
2. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmnZNagBmz68_eOxRI9r2TzOODnVagD37V-Y-nkJ2QYWHt0-7XxKFjg7aHEgG5KXKEgCOHTDGOqbCfY37ycZFD3e4CmnUL2ZHQU38ujhe7_N5R7NbsxWG80AkAnRy_EYtYd_EuJLcu)
3. [hillarylinmd.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOKrxVRUYwSIFxL1tDCY81Bnlr-vpc7UvuWADgTlt-JuxX-gZWP6mzyfVy9gmdeNBVCyZ6nlGjy9Nl1p2A8hPIrDyaJmLG8JWSvv5Pd-B18pCOMNdwJ3TP7dRwNlOVfHLp5lsn40YM3w==)
4. [patsnap.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELmRa5WOg5oZwTGs_RI972iCmuqxDLAej62yMJQzcJHmZMNSmKQOYDwHyPeCAtFmA8y2TM-Ahnt4XVvvmjF5ZeTpsp-ELF0Qngftn0SnL6y8jsNRNZwaXHkRJXoWOp2ad6ZwUJeU4k4Dhg3wIquSneGXAv1OlQo4KRK32w4O9IV4zy5JIS3X_H)
5. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGVU8z1_nWWMyAwSXTCSQnfUhTUl3Y6q48Pi8FEBuHFJDyqoRrzphlNqurI32LzR9tb7ZeAOowU3nMrfVvAe6K9ezRG53GwFJ_gN9liLDa7VkvGw0RYvK4xPTmWgonlgFTI1h02zzA=)
6. [augmentlifeshop.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGQddtImyYhpwaFzIRB7ASPgQsnxGsZCrDirZtQj0ek2ACI3fr0umdV-_AM_H80GhBIlOLMjo5zXb5RPq2m4mpFdMixyoG6shp6nTO9B2LlEUQ1UgqDgbKLGlWQBGreidWZ-TFYsakLTEirUc0yMmI7iRHTVbZP9JIS66kEoni0pZs507e65Ye1JH9i43f9lagpkCDUKsGo5XfAkX7fFZYaX4A=)
7. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEc3fBbtGQEqkzUl-SAKe63-cYN8L7DQ6FkPo1gzEfyeXa-M9RaT3l5IZNvqYzddYl611YvssBH90vZWTo8oFsAIo_9Z-YhxtXCSAbXrIx_IIvzmGhERn1PmFkeVvJjz1MLlj7r902t3lm9nGBipt6-72kc6m1DsjQl6j44RDaVauilk1SlFXY-H0SmMDuokCfR_Q==)
8. [myamericannurse.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGPcck75uQCZoGeNPpGX21ZoWGrdbGHeF0AaUhyHGH9YU8g-u5RYpX18bOcoc8nxFKr8N__p6wLBVmwutnDWcp-qFFSgdnFMQaDBmEyPu_1HXiZeBU0RjIg5yuLlVaXep8aTFFnqDGqJl6Qdx9iV64U-nFj0oMfvWlK)
9. [foodmedcenter.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1scBx4HlionS8eYPod8QvrXaP-0Lnievlcg_7WlvrXeSe09YIJo_vrgDRyinAYoEQaoB3XOdaRu1cqP1Dy12FEw4ZjY4tDNaTsTiDHhM8-KiD_qVLIgVKgnyZBVEzKvn8dpTQ)
10. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHrFYBF4unwne_pDGXUz0SYkWQY8MT_Aipn0oUUSsN0TFiy1M29f9J1L-BGCSwEbB5u4ntccGE0YssaUmynXugBi-p2F9UJUlF8Kc4j3TkRjZ4juPD3xhIh0X55WlYlPm_z7X8t6HuOguqKvWJLn0pWlss6JzryXHwtMFDoEBaHvO2gX3ZrPejNbOhpP0aOnhEXqYlu3GS6yT2OFt3cKf8rnCwg9lcQpJCALvds4mVQGGtZWcHOz9ghTLc=)
11. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ_018ZKLS7zsuo-tpZ2W6z_oh_CTg8g6xMyPLCx5maWXMD0_Bulv2GkOjYtA_3esEXojSiWWtl77tMul0rCm8XUsBHdY0VHjny95se9ZsRym2sHnf_YQEer9iUxE2lJDx5SrRqNC-)
12. [nad.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAg3XxKKl9XuW8peYBQRfNtJYB88dKfpSsycDpSvA-PywqHpnq3AhsJ_dZljQfkZ5z8Y7rsNT81BKHgF1aZQYOdLg9BWYgj-1Z9yZ8svHZbn_VCDqSzT0Sm4vsecpOh2k59BE1iTR5voknUUBTv47tyAm9FOkUIq6zZcZAK_OZNaExh_ut_TcaitzY7FZq1Zae0YPsE6gi)
13. [wisc.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjdNGP8hsExcZgxRVZsbGVO2IXeE6JREENij7hrYv0dRLr-DLGoAsOd7Lslzy9pc3m2ZNj7PQRRHPIns_1cXE6gjOM-eODCPW8AMIdj2kGjz04mPK8f-jYT-I4PcQ3JEr9FeddXaS8K1gZaQwc2z_amc0L5uD9D7hMxZ-1nXVGG9N-BOGT09v2tTx6vnSGT6VJB1I7ZvhLN731lVLcYiBUAu7JJtEYdXvV)
14. [nad.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFgwNttp6Te940lvlKwFRVzhLB9qc6qXpO3fmqV11OE0a0-2mJ5ioVpzpeBce-lr_h6KvEWf3zMhqj_zbe_X0mEzGokJm4OwQXGs97PvCN_j5eVNehqSNE5wwrxkCEwUNEdolefFgnZ-pK_yeGfuB__kL9TK7P_93mglT5ETGY-w62WLfAGx205UK6M9NdfgBDhG2onfSNWpg==)
15. [gethealthspan.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEbug8-QfOe3bVQv9aXxYUBxHokvpf-G5eHeYB7VU4d5T7bOuf740tRZLYv95q2MfmMA4PILX4Vc-CHoq-z-YHHSAd_tSFnEMEwsaS0YUeqwwMa9Qv-EyWerYRqdTDiw5RFx3jx3cr5_noF6MkPlftdAdKTat0RxUTpPUyoD2cMw-LQGhVKGA==)
16. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGO_5ReiwrwcPu3eSaQTK7cIntEBtP_g5tw9FNIulNI4kGR6iqW0MQy09YgUOlAgEM69wQU7loPxUD1svgSNCsOqp5pvztLFx6VHKGPaLgU0VphePcTUBHNc-dZYZcNHvGZnpzuCpOZU4PvO26WZhhGyGkSf8-IB1YK8-_oOFx_3QhKOHBSLYCfBxJI8BCpBVrgu8VGVRyffdD68CmTzJZBw5rqt66H7kqyQcxp)
17. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFU5FSxaDw3C-4r75LkDrp8LrJI7u9USUEkXrO3ETaFpuZ5ylIs2WAousRt32r4f_4JRi2iah-8tJCKKdBBIvLqgXa4DsgC4eiEeW-cBW8HDeweEM6i3QcUUBxJZckbJVquR6e-JFg=)
18. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGrNa6NsqvxpMB7GYMctMbMLiXYpVJlE51rLRF5iLhahvy3goRsgb21piga5EIRMaf4L_n6Qm9winOMzNQXVYVCX13-ua9MwAMPtmPEg1wF1JfVYpoKm8zMkLBYwNg5USPntoTJkXM=)
19. [gethealthspan.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGlPsGfo2wFw6gGR8dgw5UMgR9vERWGnXIGY066pHRT-tm_ZhWinCmM6BFBgEoEoG-SvRDYNfwcze02Fgw3HaCRmqYJr10lTmwCunwOYod36ue-WC_ZUZ1mw_I99MgEX-MGBMyLUHRQ9hXKsdx79Brz-dLOQj3sM4R2T9edmXg6b78b)
20. [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGmn-kr0U1dZYGkjKMl0M-KEKIerPL-uIumDONKafIm2GbroTXZqu2MWQ_RX16gfTYR7dYlBnYoEFCoFH5_d9h2g0l4T1gHYff7thaVrHt41-Zs-5G7G9mXC4gQFfuqI5WUyPTa4sFP7FTHLTx-BD6qhAi3eV2PLYMRwSusJq3bjB_hJDE1gesVYDE)
21. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEaJt2nKM-yZzCC-0EaZTyziSeyABHtNKV5qTXpr1SOTSOih23yI_JgBxLIO3csNXcUiQ2N-IehXCKGy2ybkchrKEAkTXkoFMzcAGpN6KQ2jbqkCrW-SUFGlgutAb7TzJDszAr37Jj9AegBBnh4rmCy_GRFlSIWz58ZLCRgGPLFElNeu1wDvxa94VCL63wuTxYmw4Ca_Z6E)
22. [valhallavitality.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGjE8guswzDa6xzE-NUACKGcLlQEtiDTG0_JAQOXDSgnNBjErzEdgYV3HjsFQyBGQhM0CGlp8NNEgHEV5gqe8d7mSUu0exSapFxczx-kA5ohSEUlXItNCb5HKPxvOHa-VmKz-iV9-v330MSa5UKLoeWphoVHNcnVHcUtk5ds-oTxx503QMb0aHDxg==)
23. [drugs.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHc_33iH7n6OBxRhEH1J0qHZiz5rzp0emKcfgJd_QAYx20ulY4-i23mjsBw6odU8lvZ5u_et8gQt82IJz01T37BW4bPzxstfh8Af9zNID-WeBWwS04_HbE2wOWU5ekNvhE=)
24. [rapamycin.news](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFthf8xL49Emllbqw-2Rg4dfzbfbLhmmAOeYrqspJ0bnv3LNbbeFUC2B3l5zZh_w5jnC4tP8vSIPWJSt4tLJ121O9Vmu4NzbuWPcgrYqpp6n1hu3H_bgGT3uWejn-XsJppcfFQh3lT-Qj_TOSy6ifMl3ZelSYclf731XXzG)
25. [ubiehealth.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF5N6NKvHhm2eIJ6ItQNqoupoZbaniPj26Fe30W7_cSrXYQPlU03u6H2o64IK7iW-Tiu_GSoRyr140o9Mnp_xV2hA9ldnO7cYHQbyDaJHNRuiiR9aKJZhsR-Ns5vbEgOEycnENiQeAZastzftAnrrb2dTo9w9s4LIker8lnh56XaYmx-kNCB66s3icRGVJCpw==)
26. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZMJe0Ey_bPbnnZOYKPrZdtsGkTNHyEIeEIvWsXSyuXclG8qZNWAGv19yYDc1_2hvAhV8cjOx8O1nS9n2oWLexVmO2RAoEef-mZ3AXrxCCWOga9UAP_UQZ-Cu5VifIJBFi5aPv2cPF)
27. [lifespan.asia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE-qDoZuvVaAdOeBgQb3sOzt8Ok6_Pf-uYVGpRlBE80D3C-z4kodNCNpv7dvKSya5rnH7qVk6E648ZoKTPVv3RUXih0m8hmBDkFHl_bUHrXhZl9rmO360kmIzsXvy-PhK_cwtN8We3eCHcbUpSNDzkAZ677UKUc3b60Ced6eNYZaloPIGPzsxEK6cabElPzsMvg19J8brnVp3_cH4_wzq1UAvXvuFTvfZZ2OL3xqQ==)
28. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEA7vmKqOZqo75s0oJ1_-XdCuxaub7v-MZ3oNx7hLol7r-PIw-qLRRcWTJc1Q5hRNR-2iMoqrUMFiL-G5SWE9HtaFLlct-v4FWL8iS1nsN_iWn2rwq6mNKRiSr714h7kX7vcNRGmfIMGgXZLe8LGZ2geMovNS55akdQ06a_g0jRXdCOHIW5JJdfmjxaCw5wXJsR9F2wl6tkdXoCqJRhuA==)
29. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4saH9rtoTpyME3FRc616Ge60sE7u8xOHXld7PkH-N_NXPpniaTBpRuW9aYxCXwoFtlwkxHz6GgK2aL5L_X1Ttg6-SYCs38SShn8NwgJeSFiGxXZEJK22nIvQI6r4mY3mlNbaRygSn)
30. [lifespan.io](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGN97qg2G56tMZbWZaPwttF2GtYdQaGAKoiPYek_PWMaL_sKjPXnaym1B6_UfDBuwfsOhhHhiQIC9uBMqKhAOBlWPk8THon7s0RuBDWf8uBwzS1mDEcgPey4KU9RqfVonwIs91_zrfWdEb0dzf-TJFshTM0zJEzG7qysP-1jM7L-NE=)
31. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnGkvr6jFiSV_eIC0ZuxwV9R-1KD38xmAli47exoVundlMWBmWZ1s5qJ4zPDZrzHTJXNH_05NolOGjUsmn8z1ehXTQBE_3WVoa4EqDz4OmRnjrQO2AOopxADnjAzTogE2zgRgSC9OlmEgOtdFlvHL8EiONMmgK1A66wnbxkPpy9rnJlHKE2b8rCturjscuq0-EEV1UTQYVP4Wa7Kip-o03hT8y5qM9bxhVJkn3ar1_Df_mjaOSarbSVp_65c4NDFJTtQ==)
32. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-N75TeIfzHuw8ZMyn6O1xvwNoPbpXdOFin7zJYd8P7y6rnAEn9dmA777cE14BPMSjALl16c7A7ofEy9gF3zXYCeZkAaQ1EIcfKyZ5Dwn2tw16U5yyJ0whSWQXFQ==)
33. [substack.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtlgcwjxfLrVcSmLQo2847XZJ9L0LOSkpHDmZmSkurZVkdSl_VA0mm0q0bBnPxXjZIKpWE569ezegXt2As-nsCQ2cR9_tg8sBfBtXSDFXMuXltPxHg1f1AILzhQrNP8sAtOFDIIykjCUIxK0TR2QO0TCMES3zBLYAV7A==)
34. [news-medical.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8I13WxS59-O9ILUTpYBVLgbN6keuvcepRFnMsBIaiqrwZ6-et0zEeGHQ8RpKUGP54yHQTL3da20j2ssmrUBPnWRByxkPu0w_HMLpoIMqve48L-yIb7zLLWKVzuqmG5HAqexkjV55zyHG5XKosn-JtPB-Ka8h5slfeP5wH4J28uih5tMY8FCR6WWnduloVR6MT3KgzQvg2j2veoGNhqkyiGszWFTOiTBbRqivhwaM=)
35. [columbia.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEW3r5szs5hhHWlsP1EnDQBnrPU-aes-oRRho2pg5YQXeeSC2FltaiRNj-qEYBastb9mrrpkaIBqkXaXFMwnPoiF6NoQhcg5Rk1MG4yiXaGAtEXzy0jGlZfq8qS3oexkXyyigFfEGm9verAChxyX_RGri3iX9oarfTeGsBDciy5XPqL0oxw3h_wOGy9YJBMOuUHXi5GE9lBpc1-10DyUC_xjzs1N_DW)
36. [rosewaylabs.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWpPQkaR6ST-M40-Bi7lvIqYdtVC_7WIacXvQ5a8CU1Jj1LWLvR7wsAphyP7ONRQ89i6UtQcILSGS9p65lfwUj1mPO3Sflz0vxaRBtGGwgTiTWYSEJoe8a_coSa0H6gXGtIsO4y2iwHyeKLt7yTmGRN0HmaqIgHVuXjLwrUgtKP0T8imU=)
37. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHye006WwyPQ_KH_TRXlIY9Ub1YG2gt34pnLfy5SxY_pWDWf9uBognITVc1ZCDFbkzGZ2p2I9c9uFNdOfQmj1Q5Nhnj-mpSW5XvHIL9g9Sw0MhYv7JFDbHa_3y5h_fYxyK7_CjLP5clFvEDZvmSbw1zbN71hpdaRttZjzncxDqRwNw3epxu98aNTcdFXNl3UE62ytf6SLEwB0P8jMeMbIN0BrPo7uxEU2A3ebeJbvjU8JUnMJ0yWSjKLbXvCswjGqzNPJdlLzY4sdk3OioYiPmYx7pxMD8Gqt5700T_vOXZrAdidWRle77bRx_9i8cj7tJtk8-k_ExY-8crLLW5DRvGo-bgwg==)
38. [medrxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF_PZrRGA79h-YPOffKuuoL_Y7IsK6wysHReIRtjDX5jv8Ea2LZnCXrQLIuNttE3RyBq4HueGcWxO-LEDEIZuVKfhkvTFqXYXyZ8ZxnLcX_R3yas7tTonYy-vOVYN9XakIXDWTr-UhYODbPbk-RlJUy38GsXXI-W-UeV2MS)
39. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8BXohlk9XUSokQyPReH1bLmiv2nRGl0-8qtDYV0CZvgIY1bKTahfHBkpMt6XOp6sJc96Woj_XvDkWcazskOPsXR9GNBqW5OSnn83mpaT_iQNePZQUpUUFOjdqgbRrHBUv0C6DHg93rQ2Vg9HYFWM27VofcM3Ms76Wjkj9ptAPDZuji0qYrrFLuRFo1_aIOoI3DytcWxi2nzbNb5SclRSt0qXjnzXlUEopSNKgvQ==)
40. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQESajcW71gAueZ_tBJ3zHBXxOha4BvWNtZ9poVUCWOyFvx49rNzlGh394ORcI9tiDumf7ggaJPhm_bS_wSMRPBc0uk99tEMpYRb95IxkUOzP3oT2dkjvJ7iNfPV0f1LDNYDXjnQ4OzVLiLtm_ozeB-zDTZ6ucna5mC7ooALDpDv316z8U6fQHIq0k9a13WkI2fjeYjhecM46tzffaw=)
41. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHg1z9CZU1pmtdMMrhZkZAOd7OgNx4YoB1JWUPSy9zRxY00yvEM_ho4UOPKfR7gfzkWMJKquoA2lVnoMcyum_Z5EHKukRyvy_VZ48pr7Ce-7DEI2iiNo-jENikMlWVrNWaOPYcoVAM=)
42. [digitaljournal.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHOVhAKHWESiV3eTcUIP-Lq2z3IRFWG0mUWV4t4aN2tmR6EHWRF41Ym830y4g7IcteJqgXhR0lfDfnWJ3b_H0SGkKtLZ5pIMphXTLgTLjBVLpRPkybhIPd7ykaSOgRrBuDWbBcKisi1OvOd12tSLSnCyenRTC8gfnb2_MtLEORTnuaco02rfei42u7Sq5rgbPwneACU-GXK9RWu6waUe_FIO1xTCw==)
43. [arizona.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGo454yUHDmoCrhnODL4OErNOCMawzSjKP-FCbnoFFL4W7QPoyKIApX_lNE1nxiXF1bKPIzCmh4wOH4tcYzM6Qif9ryD9GVXRasj7w0nKFwFQVMPM5Lm4cya9A3ZzmY7P_GViQdFEEkyiJd3ymeQuKzOClM5Dqvb38REpUAoluXilUugUtFP5gZLtSzGqjD3MkNLP3KC2acC3N72akR)
44. [youtube.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJ814LOFRwPZqkGPTRJEfWoqxobHiQqQt82M4Me2UQGNS8TtaSd0ijBmTj0Xk6pY-vTVHpmSrGyFdhZFJk5HiCaoUzxqO7NgWpWjDRSEJQ8CUXvjnKh8nzMvNOREvAZzk=)
45. [gethealthspan.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGMQ0ljn2T97FUOdWJtWMKjlEWy58-TnzfdLM07UYTbQiRY9KnIBlpDsltMwUy6Yxl20WATANi5B2RultYOepCFIVGKze1Pq-sLN0VwsOnL_rlx7Ja2zkTfq1rnCHrgrb22NJ5Aj2jHsZ7aCVSXCpbbzwWtA5-6ajEiKzJZKSiZl8VkuaJzPKfdr8YfXw==)
46. [arizona.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFHSd_MDqYPHXIrntBxQHI9bF_Xx_JAzCoasRzLyI36lAIv-xi9reSwmD_pnrBmG_tbmmo3cVGfuSgLf7KtOQmWb0IUtIcENFhDdHiXPzjJ0Gt5HYRQKoe05QDox519TeIEvhRZNnYTci03ysJAQFSgRy18vWHRonuT_XeEw6hRxWRTWyefNM8=)
47. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEsXMaFs6gd9_2EiLLJyaIEeH6Dq-7On4cCJ6YgoWDEeKMCks6ihrInAGPemyAHSkrARA4i_r_3EdJap3Hp3cl5JK9tsc8s-vU9ST3R3Q6V7lJMg4DQKs27YEMrwf2yOyZp)
48. [lifespan.io](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFwmQ61qTsMP8mmCBvWNNrXPXO0dwmci0mWDWqR0pQn_jwM7-z5tdGfv3GJwFTR9iooS97CpNcCCx3pwjmNrZ4oyUKF5uGhAY4lFeYowvc__5ICejWz_jgIE_N2fbqyanawhJQrGS3aqluuEjBr8_2W)
49. [weizmann.ac.il](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRQNnN9aQmhJhJj6LnwgQKoNHivsH5qjMX_CRtJ3c8S71YP_WykJPGyo9pwV8pbV8RRWD1w1imZmIJdS_ML6azyzbq9fLoK4uVEnebky9Ll1MMkIJgBkeErgWuOmo-8wO8ra45s4JcOXQ8uCajZwAbNuYZJo6tMqqu6tSzH5ZuP1KBpGThIbcpW1ZPlePr67bB_Hqu_x6VmkVyFJrWPobID-FwUnoS0MwPyYAFyA==)
50. [rapamycin.news](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEheXey-M9yrkSiZh2O_ieuyFqch9glFq4d7YF7isBl-h_4KDXTnfUbrjt36RjNOtvd5hEM_6bjdDjqkisAEYvvVv_s5shqJSmaYgjZs6eV2aW7BrJId_ok2cFrYoWfZjzK3bT_7ApPkPvBSXtyfpejGtQa1hGYBjm_uQ==)
51. [immortalitylab.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE5Jci7qa-1udymg8tmDWdCrovbYRkSQTn2h922KrBeMa8RZadze4pBoYTqyBPdY5h6K1pMAvJ8YLTARlWh9Qca6kXBS9D_g92lbOXiynlFI9UNxVBhsHVNTBE6g6FRS3YpI4U6EjQux0P5MgxPhw==)
52. [rapamycin.news](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDsjNwWh5G9P2hgQ-eu9LW2jDzriKukON-uvfanNJhfji7mUiVA2cP2hYiKMjfi6UnSN7eEyCAatFpLVEO7JMWHYYeFPM1JwxIvapudWmtoV9Rq9LEPaAoAWslyMk5ckoMCv4Vpw1mC6y9ePKDP20dCrNB)
53. [lifespan.io](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEztr8wCeNuWjsi9e1XBiyL0jgo2qh_xWh8SXxt4Pw5qWBV6EHrPPPFHenIK3seUTYD9fe-WNfss7oeLedV6la_cmSt9Lw696CeF9UH5fd_oyvY1jTLiWo0RQ3TEUE8kKCJdfm4skrYctpJXlPnBQrvauCD5A==)
54. [purovitalis.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWZ7gt7jJzIUq75FVbgVRROar1d2-nlsTPhzig43DMFzWJ2r0xacqgVMfYMnjaujELpH23foflf0nggk492vbVqsRGi3yu14e5sHVt15yukiKyirAZzJEuWmmVSEsP5B9XhFkithaYWoqihL5PjgLv)
55. [nus.edu.sg](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFTVjp40YBgsgeKa3ucRPUYELbVFmmZRfKMG4nVdXN-6knKiIWVhzG5cBSuP7GkWVBmRJjM54ZLDnYjBh_xhqIigt5IG_SrnYpYuEQ_roxDAYGCP7b6fm5n3fMxDw5r7oBd8wqoJZB18U1kYO_OEiejBSGvTbfKHfiy16lozIOyNcgDytkZ-aWn7eavUQZ2JdRQZX9dlKoL-GDZox8W4GM7t0MrCnEH2RdBJcZaIrsf9JrBQIHpDmU0OXb9CrRfztPPkpCvyt6oWBFlI-mY5XtrQJ3I43unS_xVBII=)
56. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBgQ96ycvMnpuCQVH-wtUZ8GvRvhPRTJCdN3sqRWVHgvvk8Va-Bb5o5ngxRNrmIUtxrTtncqKf_9Uix8u8sAUgST4x4r4IaIU5YEE3LY9OiIXdvcmgOABF3vjvtpijc-el4jqRj17gKQvh)
57. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJqjNd1goVlDZbNEeOPzcFQOzPeC92bHv1L0mZuxUg07CjpnvpvpJRpRbPaQJeQJSeGEbyHAHaCUh4iZYCT8e2GEGXpyeCt1YsQ4aUTKxMeg6rk_KCqg3dpNlOO_vuqv3tQMYRqvZTPoP2c3WTS_qoN3OerFHtsbQVoWRtlQbu3g5dtkNv1VeWQFduUBYZ3--03AOIa78vvHiP3t8eKlDETtWEqZxD4r41n90ilrtA2R-199jZmvlBIOBeWwDcxyJHMRnHxVSxA_2fWb4YrTxWkwmZnleMpojEYZX62Tge3P2Rz--HXWbNTtbBDdRsx1k-pECb)